Income Statement Presentation 2023
2022: Diagnostics Division sales
Sales increase of +3% driven by base business offsetting COVID-19 testing decline
Roche
2022
2021
Change in %
CHFM
CHFM
CHF
CER
Diagnostics Division
17,730
17,760
0
3
Core Lab1
7,775
7,560
3
6
Point of Care¹
3,589
3,134
15
17
Molecular Lab¹
3,450
4,174
-17
-15
Diabetes Care
1,598
1,690
-5
-2
Pathology Lab
1,318
1,202
10
11
CER-Constant Exchange Rates; underlying growth of Core Lab excluding Roche Information Solutions: +6%; 1 Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the
Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC
molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21-194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21-23mCHF, Q3 21-23m CHF, Q4 21=20mCHF.
37View entire presentation